First Clinical Genetic Test for Idiopathic Pulmonary Fibrosis Launched by Ambry Genetics

FOR IMMEDIATE RELEASE

Ambry Genetics
15 Argonaut
Aliso Viejo, CA 92656

Aliso Viejo, CA, August 13, 2007 - Ambry Genetics, a leader in comprehensive genetic testing, has introduced the first clinically-available genetic test for mutations causing Idiopathic Pulmonary Fibrosis (IPF), an incurable lung disease affecting approximately 128,000 people in the U.S.

Previously, all causes of IPF were unknown. Recent research published by groups based at Johns Hopkins University, Vanderbilt University, and University of Texas Southwestern Medical Center showed that mutations in two genes, TERT and TERC, account for about 10% of familial cases of Idiopathic Pulmonary Fibrosis and a low percentage of sporadic cases. The Ambry Test: IPF Telomerase includes full gene sequencing of both genes and is currently available to patients with symptoms of IPF or the related broader group of interstitial lung diseases.

"We’re grateful to Ambry for their investment into IPF research, and for making this test available to patients. The CPF encourages patients, especially those with a suspected familial connection to Idiopathic Pulmonary Fibrosis, to discuss this new test and its potential importance with their pulmonologist," said Mark Shreve, Chief Executive Officer of the Coalition for Pulmonary Fibrosis, a non-profit organization that provides education, support, and advocacy for the IPF community, and funds emerging research. "We look forward to continuing our collaboration with Ambry to support their efforts in advancing research into this devastating disease"

Ambry Genetics has a long-standing commitment to pulmonary medicine and to assisting physicians and clinical researchers in the application and interpretation of genetics for their patients. The Ambry Test: IPF Telomerase is the most recent addition to a rapidly-growing menu of diagnostic services in cystic fibrosis, alpha-1-antitrypsin, surfactant dysfunction, and other diseases.


About Ambry Genetics ®

Ambry Genetics is both College of American Pathologists (CAP)-accredited and Clinical Laboratory Improvement Amendments (CLIA)-certified. Ambry leads in clinical genetic diagnostics and genetics software solutions, combining both to offer the most comprehensive testing menu in the industry. Ambry has established a reputation for sharing data while safeguarding patient privacy, unparalleled service, and responsibly applying new technologies to the clinical molecular diagnostics market. For more information about Ambry Genetics, visit ambrygen.com.

Press Contact:
Aaron Schmidt
Sr Manager, Communications
aschmidt@ambrygen.com
949 457 4679

Search Results

Start your search...